24 Month Open Label Study of the Tolerability and Efficacy of an Antisense Oligonucleotide (Inotersen) in Patients With Transthyretin (TTR) Amyloid Cardiomyopathy
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2019
Price : $35 *
At a glance
- Drugs Inotersen (Primary)
- Indications Amyloidosis; Cardiomyopathies
- Focus Therapeutic Use
- 31 Jul 2019 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.
- 31 Jul 2019 Planned primary completion date changed from 1 Jun 2021 to 1 Jan 2022.
- 31 Jul 2019 Status changed from not yet recruiting to recruiting.